BioSig’s PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias
October 12, 2021 09:15 ET
|
BioSig Technologies, Inc.
Westport, CT, Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing...
Clinical Data Acquired by the PURE EP™ System Published in the Journal of Cardiovascular Electrophysiology
October 04, 2021 08:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Oct. 04, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal...
BioSig Selects Plexus Corp. as its Manufacturing Partner
September 28, 2021 09:15 ET
|
BioSig Technologies, Inc.
Westport, CT, Sept. 28, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal...
BioSig Technologies, Inc. Appoints Medical Device Industry Leader to its Board of Directors
September 21, 2021 10:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Sept. 21, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing...
BioSig Increases Installation Footprint Adding St. Elizabeth’s Medical Center to Roster of Premium Medical Institutions Utilizing the PURE EP System
September 13, 2021 08:00 ET
|
BioSig Technologies, Inc.
Westport, CT, Sept. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing...
BioSig Confirmed as a Participant of The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Virtual Symposium
August 31, 2021 10:00 ET
|
BioSig Technologies, Inc.
Westport, CT, Aug. 31, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing...
BioSig’s Signal Processing System for Arrhythmia Care To Be Featured At The Kansas City Heart Rhythm Symposium
August 19, 2021 11:00 ET
|
BioSig Technologies, Inc.
Westport, CT, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal...
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021 16:15 ET
|
ARCA biopharma, Inc.
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology
July 28, 2021 08:00 ET
|
ARCA biopharma, Inc.
Analysis in full patient cohort shows Gencaro effect compared to standard of careIn the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with...
BioSig To Host Presentations from Physician Users of its Signal Processing System for Arrhythmia Care during the annual Heart Rhythm 2021 convention
July 20, 2021 14:00 ET
|
BioSig Technologies, Inc.
Westport, CT, July 20, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal...